NOTES tech firm gains $21.5m to grow sales
This article was originally published in Clinica
Gastrointestinal surgical devices developer EndoGastric Solutions (EGS) has raised $21.5m in series E financing from its current investors. This brings the total investment in the Redwood City, California firm to over $100m. The proceeds from the recent round will help EGS further expand commercialisation of its EsophyX and StomaphyX devices, designed to perform incisionless, natural orifice translumenal endoscopic surgery (NOTES). The company EsophyX is indicated for treatment of gastroesophageal reflux disease, and StomaphyX is used for creating large tissue folds in the gastrointestinal tract. The devices are both CE-marked and FDA-cleared, and are being commercialised mainly in the US, as well as in Europe and South America.
You may also be interested in...
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.
Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.